Clinical Trials Directory

Trials / Completed

CompletedNCT06930989

Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022

Twin Threat of OSA and Hypertension on Mortality/CV-risk and Protective Effect by Positive Airway Pressure Treatment.

Status
Completed
Phase
Study type
Observational
Enrollment
148,467 (actual)
Sponsor
Vastra Gotaland Region · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders. The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies. Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.

Detailed description

Please see attached analysis plan

Conditions

Interventions

TypeNameDescription
DEVICEPositive airway pressure (PAP)Intervention as part of routine clinical care. Data from national registries.

Timeline

Start date
2025-01-01
Primary completion
2025-04-08
Completion
2025-04-30
First posted
2025-04-16
Last updated
2025-05-23

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT06930989. Inclusion in this directory is not an endorsement.